Sanofi India Ltd — Interim / Quarterly Report 2021

Oct 26, 2021

26th October 2021

The Secretary The Secretary Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor Dalal Street Plot No. C/1, G Block Mumbai 400 001 Bandra-Kurla Complex

Bombay Stock Exchange Limited The National Stock Exchange of India Limited Bandra East, Mumbai 400 050

Unaudited Financial Results for the Quarter and Nine Months Ended 30th September 2021

Dear Sirs,

We refer to our letter dated 13th October 2021 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 1.30 p.m. and concluded at 04.00 p.m. The Board approved unaudited financial results for the quarter and nine months ended 30th September 2021.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and nine months ended 30th September 2021 approved at this Meeting along with a copy of the Limited Review Report duly signed by the Auditors of the Company.

Please take the above information on record.

Thanking you,

For SANOFI INDIA LIMITED

VAIBHAV KARANDIKAR WHOLE TIME DIRECTOR, CFO & COMPLIANCE OFFICER

Price Waterhouse & Co Chartered Accountants LLP

To The Board of Directors Sanofi India Limited Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072

• 1. We have reviewed the unaudited financial results of Sanofi India Limited the quarter ended September 30, 2021 and the year to date results for the period January 1, 2021 to September 30, 2021 which are included in the accompanying Statement of Unaudited Financial Results for the quarter and nine months ended September 30, 2021 . The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ), which has been digitally signed by us for identification purposes. The Statement is the Our responsibility is to issue a report on the Statement based on our review.
• 1. We conducted our review in accordance with the Standard on R hartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
• 1. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
• 1. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP Firm Registration Number: 304026E/E-300009

Asha Ramanathan Partner Place: Mumbai Membership Number: 202660 Date: October 26, 2021 UDIN: 21202660AAAACL1271

Price Waterhouse & Co Chartered Accountants LLP, Nesco IT Building III, 8th Floor, Nesco IT Park Nesco Complex, Gate No. 3 Western Express Highway, Goregaon East, Mumbai 400 063 T: +91(22) 61198000, F: +91 (22) 61198799

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)

SANOFI INDIA LIMITED

Registered Office : Sanofi House,C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.Corporate Identity Number: L24239MH1956PLC009794Tel no: (91-22) 28032000 Fax No: (91-22) 28032846 Website: www.sanofiindialtd.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2021

₹ in Million
Particulars	Quarterended30.09.2021(Unaudited)	Quarterended30.06.2021(Unaudited)	Quarterended30.09.2020(Unaudited)	Nine Monthsended30.09.2021(Unaudited)	Nine Monthsended30.09.2020(Unaudited)	Yearended31 12 2020(Audited)
1. Revenue from Operations	7,545	7,891	6,866	22,687	21,816	29,019
2. Other Income	147	171	149	581	736	898
$3$ . Total Income $(1+2)$	7,692	8,062	7,015	23,268	22,552	29,917
4. Expenses(a) Cost of Materials Consumed(b) Purchases of stock in trade(c) Changes in inventories of finished goods, stock in trade and work in progress(d) Employee benefits expense(e) Finance costs(f) Depreciation and amortisation expense(g) Other expenses	1,4561,996(130)1,07451431,161	1,2401,7794001,1205211881	1,3521,592(135)1,09642061,039	4,2635,4163053,257145583,093	4,4314,4385073,536146183,443	5,9146,0475754,608188224,744
Total Expenses	5,705	5,636	5,154	16,906	16,987	22,728
5. Profit before exceptional item and tax (3-4)	1,987	2,426	1,861	6,362	5,565	7,189
6. Exceptional item (Refer note 3 & 4)	4,892		(2)	4,892	(495)	(417)
7. Profit before tax (5+6)	6,879	2,426	1,859	11,254	5,070	6,772
8. Tax expenseCurrent TaxDeferred Tax	1,714(133)	676(33)	536(6)	2,930(216)	1,643(119)	2,110(114)
9. Profit for the period (7-8)	5,298	1,783	1,329	8,540	3,546	4,776
10. Other comprehensive income (OCI) (Net of Tax)		$\blacksquare$	$\blacksquare$		(37)	(88)
11. Total comprehensive income for the period $(9+10)$	5,298	1,783	1,329	8,540	3,509	4,688
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity					۰	20,960
14. Basic and diluted earnings per share (not annualised)	230.04	77.42	57.71	370.81	153.97	207 38

ASHA RAMANATHA ASHA RAMANATHAN ${\sf N}$

Digitally signed by 15:39:39 + 05'30'

The statutory auditors have digitally signed this statement for identification by purposes only and this Statement shouldbe read in conjunction with the review reportdated October 26, 2021 RAJARAM Digitally signed by RAJARAM NARAYANA NARAYANAN Date: 2021.10.26 N 15:18:26 +05'30'

Notes:

• The above Results have been reviewed by the Audit Committee at its meeting held on October 25, 2021 and approved by the 1. Board of Directors of the Company at its Meeting held on October 26, 2021. The statutory auditors have carried out a limited review of the above results for the quarter ended September 30, 2021.
• This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), 2. prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
• 1. The Board of Directors of the Company at its meeting held on July 27, 2021 approved a transaction for the slump sale and transfer of the Company's Nutraceuticals business, on a going concern basis to Universal Nutriscience Private Limited for a consideration of $\bar{\xi}$ 5,870 million including debt like obligations, subject to customary working capital adjustments. The transaction has been closed on September 30, 2021, subject to final working capital adjustments and consideration of $\overline{3}5.876$ million has been received on the closing date.

During the quarter and period ended September 30, 2021, the Company has accounted for gain from transfer of Nutraceuticals business amounting to $\bar{\tau}$ 4,892 million (comprising debt like obligation taken over by the purchaser $\bar{\tau}$ 196 million, intangible assets adjusted ₹ 827 million and transaction costs ₹ 337 million), which has been disclosed as an exceptional item.

• During the year ended December 31, 2020, the Company had transferred its Ankleshwar manufacturing facility to Zentiva Private 4. Limited. The final consideration after working capital adjustments of ₹3,001 million has been received in full. Costs relating to this transfer, aggregating $\bar{\tau}$ 417 million, were disclosed as an exceptional item in the year ended December 31, 2020.
• The Company has a single business segment namely 'Pharmaceutical Business'. 5.
• 1. The figures for the previous period/year have been regrouped/reclassified, wherever necessary to conform to current period/year classification.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated October 26, 2021

Digitally signed by ASHA ASHA RAMANATHAN RAMANATHAN Date: 2021.10.26 15:40:04 +05'30'

October 26, 2021

SANOFI INDIA LIMITED

RAJARAM Digitally signed by RAJARAM NARAYAN NARAYANAN Date: 2021.10.26 AN 15:18:54 +05'30

RAJARAM NARAYANAN MANAGING DIRECTOR DIN: 02977405